{
    "clinical_study": {
        "@rank": "124317", 
        "arm_group": {
            "arm_group_label": "Single Arm", 
            "arm_group_type": "Experimental", 
            "description": "Neoadjuvant chemotherapy with XELOX: Xeloda, po, 1000mg/m2/12h daily, day 1 in the afternoon until day 15 in the morning; Oxaliplatin, iv, 130mg/m2, day 1; and Bevacizumab, iv, 7.5 mg/kg, day 1, during the first cycle (each cycle has 3 weeks).\nFollowed by chemoradiotherapy, 50 Gy/25 fractions during 5 weeks plus 2 cycles XELOX and Bevacizumab: Xeloda, po, 1000mg/m2/12h daily, day 1 in the afternoon until day 15 in the morning; Oxaliplatin, iv, 100mg/m2, day 1; and Bevacizumab, iv, 7.5 mg/kg, day 1.\n6-7 weeks from the last radiation therapy, Total Mesorectal Excision (TME) surgery will be performed.\n3-4 weeks after operation, 3 cycles XELOX (the same as the neoadjuvant chemotherapy) and 2 cycles Xeloda (po, 1000mg/m2/12h daily, day 1 in the afternoon until day 15 in the morning) will be administered."
        }, 
        "brief_summary": {
            "textblock": "We presumed that the addition of a monoclonal antibody Bevacizumab into radiation therapy\n      and combination chemotherapy could results in improved pathologic tumor regression grade\n      (TRG) in locally advanced nonmetastatic rectal cancer."
        }, 
        "brief_title": "Preoporative Bevacizumab, Radiation Therapy, and XELOX Chemotherapy for Locally Advanced Nonmetastatic Rectal Cancer", 
        "completion_date": {
            "#text": "March 2020", 
            "@type": "Anticipated"
        }, 
        "condition": "Rectal Cancer", 
        "condition_browse": {
            "mesh_term": "Rectal Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Giving\n      bevacizumab together with radiation therapy and combination chemotherapy before surgery may\n      achieve promising improvements in pCR rates, we designed this Phase II study in patients\n      with T3/4 or N1/2 loco-regionally advanced rectum cancer, to examine the efficacy and safety\n      of the addition of bevacizumab to a regimen of capecitabine and oxaliplatin in combination\n      with pre-operative radiation."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically confirmed adenocarcinoma of the colon or rectum.\n\n          -  T3 or T4 adenocarcinoma or node positive colorectal tumours.\n\n          -  Appropriate staging investigations of the primary tumour, either endorectal\n             ultrasound or pelvic MRI.\n\n          -  Male or female aged 18 to 70.\n\n          -  Have a performance status ECOG of 0 or 1.\n\n          -  Have a life expectancy greater than 6 months.\n\n          -  Adequate organ function and coagulation parameters as measured by: WBC > 4000/mm3,\n             PLT > 100000/mm3, Hb > 10g/dL, ALT < 1.5X ULN, AST < 1.5X ULN, bilirubin < 1.5mg/dL\n             Serum creatinine < 1.8mg/dL.\n\n          -  Patient consent.\n\n        Exclusion Criteria:\n\n          -  Known to have clinical or radiological evidence of distant metastases.\n\n          -  Evidence of intestinal obstruction (except for those after enterostomy).\n\n          -  Patients with a past history of colorectal surgery (except for enterostomy),\n             chemtherapy, radiation, biotherapy or targeted therapy.\n\n          -  Pregnant woman OR women of childbearing potential with a positive pregnancy test at\n             baseline or lactating.\n\n          -  Sexually active males and females (of childbearing potential) unwilling to practice\n             contraception during the study.\n\n          -  Patients with a past or current history (within last 5 years) of other malignancies,\n             except for the indication under this study and curatively treated basal and squamous\n             skin cancer or in-situ cancer of the cervix.\n\n          -  Patients with mental disorder unable to complete the informed consent.\n\n          -  Uncontrolled hypertension.\n\n          -  Clinically significant (i.e. active) cardiovascular disease for example:\n\n        cerebrovascular accidents (<=6 months), myocardial infarction (<= 6 months), unstable\n        angina, New York Heart Association (NYHA) grade II or greater congestive heart failure,\n        serious cardiac arrhythmia requiring medication.\n\n          -  Moderate or serious proteinuria.\n\n          -  Known hypersensitivity against experimental drugs."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "45", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 23, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01818973", 
            "org_study_id": "6901061"
        }, 
        "intervention": [
            {
                "arm_group_label": "Single Arm", 
                "description": "po, 1000mg/m2/12h daily, day 1 in the afternoon until day 15 in the morning, 8 cycles", 
                "intervention_name": "Xeloda", 
                "intervention_type": "Drug", 
                "other_name": "Capecitabine"
            }, 
            {
                "arm_group_label": "Single Arm", 
                "description": "iv, 130mg/m2, day 1, 1 cycle during neoadjuvant chemotherapy and 3 cycles in adjuvant chemotherapy 100mg/m2, day 1, 2 cycles during concurrent chemoradiotherapy", 
                "intervention_name": "Oxaliplatin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Single Arm", 
                "description": "iv, 7.5 mg/kg, day 1, 3 cycles during neoadjuvant chemotherapy and concurrent chemoradiotherapy", 
                "intervention_name": "Bevacizumab", 
                "intervention_type": "Drug", 
                "other_name": "Avastin"
            }, 
            {
                "arm_group_label": "Single Arm", 
                "description": "Intensity-modulated radiation therapy, 50 Gy/25 fractions during 5 weeks", 
                "intervention_name": "Radiation", 
                "intervention_type": "Radiation"
            }, 
            {
                "arm_group_label": "Single Arm", 
                "description": "Total Mesorectal Excision (TME)", 
                "intervention_name": "surgery", 
                "intervention_type": "Procedure"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Oxaliplatin", 
                "Capecitabine", 
                "Bevacizumab"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Rectal Cancer", 
            "Bevacizumab", 
            "capecitabine", 
            "oxaliplatin", 
            "preoporative IMRT"
        ], 
        "lastchanged_date": "March 23, 2013", 
        "location": {
            "contact": {
                "last_name": "Yuan-hong Gao", 
                "phone": "+86-20-87343385"
            }, 
            "facility": {
                "address": {
                    "city": "Guangzhou", 
                    "country": "China", 
                    "state": "Guangdong", 
                    "zip": "510060"
                }, 
                "name": "Sun Yat-sen University Cancer Center (SYSUCC)"
            }, 
            "investigator": {
                "last_name": "Yuan-hong Gao", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "overall_contact": {
            "email": "gaoyh@sysucc.org.cn", 
            "last_name": "Yuanhong Gao", 
            "phone": "+86-20-87343385"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China:Institutional Review Board of Sun Yat-sen University Cancer Center", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "The pathologic tumor regression grade (TRG)", 
            "safety_issue": "No", 
            "time_frame": "March 30, 2015"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01818973"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Sun Yat-sen University", 
            "investigator_full_name": "Yuan-hong Gao", 
            "investigator_title": "Associate Professo", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "5-y overall survival", 
                "safety_issue": "No", 
                "time_frame": "March 30, 2020"
            }, 
            {
                "measure": "Occurence of toxicity", 
                "safety_issue": "Yes", 
                "time_frame": "March 30, 2015"
            }, 
            {
                "measure": "5-y local relapse free survival", 
                "safety_issue": "No", 
                "time_frame": "March 30, 2020"
            }
        ], 
        "source": "Sun Yat-sen University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Sun Yat-sen University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2013"
    }
}